Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Accumulated Expenses for 3 consecutive years, with $27.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 9.79% to $27.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $27.0 million, a 9.79% decrease, with the full-year FY2024 number at $29.9 million, down 30.96% from a year prior.
  • Accumulated Expenses was $27.0 million for Q3 2025 at Inhibrx Biosciences, down from $28.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $43.3 million in Q4 2023 to a low of $23.9 million in Q2 2024.
  • A 3-year average of $30.7 million and a median of $29.9 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: plummeted 30.96% in 2024, then increased 19.35% in 2025.
  • Inhibrx Biosciences' Accumulated Expenses stood at $43.3 million in 2023, then tumbled by 30.96% to $29.9 million in 2024, then decreased by 9.79% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Accumulated Expenses are $27.0 million (Q3 2025), $28.5 million (Q2 2025), and $32.8 million (Q1 2025).